Pool
We examined the effects of chemical blockers on albumin and TBG binding, using equilibrium dialysis to measure free fractions of T4 analog and T4. We then created FT4 assays in which various concentrations of chemical blockers were used to demonstrate their effects on FT4 estimates in patients with low or increased TBG concentrations or who were pregnant. We found that chemical blockers do displace T4 analog from albumin, but also displace T4 from albumin and, in high concentrations, from TBG as well. It is this displacement of T4 from TBG by chemical blockers that resulted in "TBG dependence" of DPC FT4 estimates. This problem has been corrected in currently available versions of the DPC FT4 kit.
An estimation of free thyroxin (FF4) concentration, often as a free thyroxun index (FF1), is the most frequently used test for thyroid dysfunction. 3 In the late 1970s, methods were introduced for estimation of FF4 based on immunoextraction of thyroxin (T4) from the patient's serum by anti-T4 antibodies (1,2). While several techniques for the quantification of immunoextracted T4 have been proposed, assays involving a radiolabeled analog of T4, able to compete with T4 for antibody binding but not for binding by T4 binding proteins in serum, have been most widely adopted in clinical laboratories (3). The quantity of immunoextracted T4 is related to actual FF4 concentration by reference to similarly immunoextracted FF4 calibrators, themselves standardized by a reference equilibrium dialysis method. Altered alaninesidechain T4 analogs are used in these FF4 assays, because they may not be bound by thyroxin-binding globulin (TBG) or transthyretin (TBPA) (4). It quickly became apparent, however, that these T4 analogs are bound by albumin, leading to dependence of the FF4 estimates on serum albumin concentrations (5, 6). In the absence of an analog with the desired characteristic of no affinity for albumin, two approaches have been taken to limit the binding of analog by serum albumin in FF4 assays: (a) use of excess anti-T4 antibody, thus favoring analog-antibody over analog-albumin binding (3), or (b) chemically inhibiting analog-albumin binding, thus permitting analog-antibody association in a limited antibody concentration system (7, 8) .
Initially introduced by Amersham (9), excess-antibody FF4 assays are significantly affected by albumin concentration (10). An analog FF4 assay involving chemical blockers was first introduced by Diagnostic Products Corporation (DPC) in 1982 (7, 8) . The chemical blocker concentration was increased in late 1985 to eliminate residual analogalbumin binding still present in the initial kit (11). While apparently free of albumin effects, FF4 estimates made by using this re-optimized assay appeared to be TBG dependent (12, 13).
We studied the effects of chemical analog-albumin binding blockers on both an altered alanine-sidechain T4 analog-(DPC) and T4-protein binding, using the DPC assay system as our model. We find that although analog-albumin binding can be eliminated by using chemical binding blockers, these blockers also displace T4 from albumin and, at high concentrations, from TBG as well, resulting in a significant dependence of T4 estimates on the amount of T4 displaced from TBG in patients' samples relative to that in the assay calibrators. This finding explains the apparent "TBG effect" observed by users of this DPC assay.
Materials and Methods

Equilibrium Dialysis
In order to establish their effect on binding of T4 analog and T4 to albumin and TBG, we estimated dialyzable ("free") T4 analog and free T4 by equilibrium dialysis in the absence and presence of the chemical blockers, 2,4-dinitrophenol and sodium salicylate. We subjected pooled serum, human serum albumin, and TBG, enriched with imIlabeled T4 analog or 'I-labeled T4, to equilibrium dialysis against buffers provided by Diagnostic Products Corp., Los Angeles, CA, which contained various concentrations of chemical blockers. Buffers, chemical blocker concentrations, and the thyroxin analog used here are described elsewhere (14). We used serum obtained from euthyroid patients with normal, above-normal, and subnormal TBG, and from women in the first or third trimester of pregnancy. The specimens were pooled to provide adequate volumes for study. We used five serum pools, the total T4, T3 uptake (T3U), and TBG concentrations of which are listed in Table 1 . 
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Human serum albumin was stripped of endogenous thyronines by use of charcoal (provided by DPC). We weighed albumin to produce solutions containing 18, 36, and 56 g/L. These solutions were found to contain 11, 16, and 19 jg of T4 per liter.
TBG was purchased from Scripps Institute (lot 238). We prepared three concentrations of TBG, putatively 5, 25, and 70 mgfL (later referred to as TBG 5, 25, and 70 solutions). We measured the TBG in these three solutions to be 1.0, 13.5, and 37.2 mgfL with the Corning TBG assay (Ciba Corning, Medfield, MA). Although this TBG was supposed to have been stripped of T4, we measured 11,44, and 147 pg of T4 per liter in these pools.
We were provided six buffers by DPC, labeled 1-6. Buffer 1 contains no chemical blockers.
The remaining buffers contain increasing concentrations of the two chemical blockers of analog binding by albumin. The relative ability to displace T4 analog from albumin increased from buffer 2 through buffer 6 (14).
Each pool was enriched with radiolabeled analog or T4, diluted 21-fold in buffer, the same dilution as used in the current DPC FF4 assay, and dialyzed as described below.
Tracers were freshly iodinated at high specific activity, and contained 1.0 g of charcoal-stripped albumin per liter, for stabilization. The T4 analog was the altered alaninesidechain derivative that DPC uses in their analog FF4 assays (14).
The dialysis protocol and calculations were as follows: We added 10 4, of tracer (about 1 000 000 counts/mm), either analog or T4, to 0.5 mL of pooled serum, albumin, or TBG, and incubated for 60 mm at 37 #{176}C in a temperaturecontrolled water bath. We then added 2.0 mL of buffer 1-6, and mixed well. We pipetted 2.0 mL (containing 0.4 mL of the pool) of the above mixture into dialysis bags, which were suspended in 20-mL polypropylene tubes respectively containing 6.4 mL of buffers 1-6; the total dilution was 1:21. We included dialysis blanks, replacing sample with buffer, to account for binding by the albumin included in the tracers. We incubated the dialysis tubes overnight at 37#{176}C in a shaking water bath. We then checked volumes, noting any alterations either inside or outside the bag. We pipetted 1.0 mL from inside the bag and 1.0 mL from outside the bag into tubes and counted the radioactivity in a 20-well gamma counter, with associated data reduction (DPC).
We calculated the free fractions as follows: Inside bag: bound + (2/8.4 free), i.e., 0.24. Outside bag: 6.4/8.4 free, i.e., 0.76. We counted (1/6.4) x 0.76 free outside the bag = 0.12 (the factor is thus 8.33).
Total activity = (counts in 1 mL from inside x 2) + (counts in 1 mL outside x 6.4).
% free = [(counts in 1.0 mL of buffer from outside the bag) x 8.33/total activity] x 100.
lmmunoextraction
In the DPC FF4 assays an anti-T4 antibody-coated tube is used. We measured the effect of chemical blockers on T4 analog and T4 bound by the antibody-coated tubes. We placed 50 4, of each euthyroid serum pool enriched with either 'I-labeled T4 analog or lmIlabeled T4, along with 1.0 mL of buffers 1-6, in antibody-coated tubes. The tubes were incubated for 1 h at 37#{176}C, counted for total radioactivity, decanted, rinsed with distilled water, and re-counted. Results were calculated as % extraction = (counts in tube/ total activity) x 100.
Assays and Patients
We created five FF4 assays by diluting lmIlabeled T4 analog in buffers 2-6 (there was no antibody binding in the presence of buffer 1, which contained no blockers; all T4-analog was bound by albumin in the presence of buffer 1). We measured apparent FF4 in serum samples from 87 euthyroid patients (none receiving replacement thyroid hormone) and from 78 pregnant women-40
in the first trimester and 38 in the third trimester of pregnancy-using each of the five assays. The protocol followed was the same as that for the production version of the DPC FF4 assay. All assays were calibrated with the same calibrators (DPC F4C 3007-900C). Calibrator concentrations were 1.3-83 ng/L. We experienced similar replication (between run) for three FF4 control pools (CVs were 5.9-9.1% for pools with FF4 concentrations of about 10 and 25 ng/L, and 9.5-16.4% for a pool with FF4 concentration of about 3 ng/L for all five assays). We estimated FF4 in these same serum samples, using the Amersham Free T4 measured by equilibrium dialysis is shown in Figure 2 . The effect of the albumin added to stabilize the tracer is seen in the results obtained for the dialysis blanks (Figure 2a) . T4 was displaced from albumin by the chemical blockers (Figure 2b) . The percentage of total T4 displaced was lower than the percent of total analog, but there was carrier T4 present in the system. The dialyzed fraction of T4 was relatively high in the TBG = 5 solution (Figure 2c Analog was displaced from serum binders by very small concentrations of blockers in proportion to albumin concentration (the low TBG serum pool also had the lowest albumin concentration) (Figure 3a ). More analog was bound by albumin in the first-than in the third-trimester serum pool. Differences in displacement were less evident at higher blocker concentrations (buffers 5 and 6). In contrast to T4 (Figure 3b) , there was no evidence that analog was bound by TBG or that TBG is important in determining free-analog concentration.
The dialyzed fractions of T4 in buffers 2-4 were inversely proportional to TBG concentration (Figure 3b) , as they are in other equilibrium-dialysis FF4 assays. The addition of blocker resulted in slight increases in the free fractions (buffers 2-4), consistent with displacement of T4 from albumin. There were marked increases in the dialyzed fractions of T4 in buffers 5 and 6, which contained the highest concentrations of blockers. Analog and T4 bound by the antibody-coated tubes are shown in Figures 4a and 4b .
Free thyroxin index, Amersham-measured FF4, and FF4 estimated by the DPC systems in buffers 2,4, and 5 for nonpregnant euthyroid patients are related to TBG concentrations as shown in Figure 5 . The same measurements in pregnant women, related to albumin concentration, are shown in Figure 6 . Results for the DPC buffer 3 were intermediate between those for buffers 2 and 4, and results for buffer 6 were similar to those for buffer 5. (/) Chemical blockers used to displace analog from albumin must not displace T4 from endogenous T4-binding proteins.
DIscussion
(g) Assay conditions should affect labeled analog-anti- binding of labeled analog and T4.
ButterS
Chemical blockers of T4-protein binding have been used Fig. 4 . Percentage of antibody-extracted thyroninefrom low-and highfor many years in total T4 assays. Anilinonaphthalene TBG pooled serum samples in the presence of buffers [1] [2] [3] [4] [5] [6] sulfonic acid, thimerosal, salicylates, and phenytoin have a, 14 analog. b, 14 been used for this purpose (17) . Any of these compounds in sites (14, 15) . Orthosubstituted phenols have a structure analogous to the phenolic hydroxide in thyronines, and they may be used to saturate albumin binding sites. The influence of ortho groups on the strength of phenolic acids differs. Ortho carboxylic and mtro groups affect the acid strength of phenol more than ortho iodo substitution does, which explains why such compounds displace thyromne or thyromne analogs from albumin.
The outer ring is identical in both T4 and T4 analogs: a phenolic hydroxide with two ortho iodine atoms. The disassociation of the phenolic hydrogen is influenced by the adjacent halogens. The strength of albumin binding of T4, with two ortho iodine atoms, and of T3, with just one, is therefore expected to differ, but alanine-sidechain alterations probably are too distant from the outer ring phenolic hydroxide to result in mesomeric influences on its dissociation. The strength of albumin binding to T4 and 14 analog through the outer ring is therefore likely to be essentially identical. Thus we may expect that phenolic analogs will disrupt not only T4-analog-albumin binding, but T4-albumm binding as well. There may, however, be some binding differences, depending upon the alanine-sidechain substitutions.
The association constant for albumin and T4 is approximately 5 x i0 and for T3, about 2.5 x iO. In contrast, albumin has a relatively low affinity for most aromatic hydroxide groups. 2,4-Dinitrophenol possible to achieve this saturation at lower concentrations than are required for either compound alone.
Increasing blocker concentrations may be expected to displaceT4 or T4 analog from albumin and then, ultimately, T4 from TBG. Displacement of 14 from albumin by blocker (in both the calibrators and serum samples) is expected, but may produce a more nearly accurate FF4 estimate than is produced if analog-albumin binding is disrupted by excess antibody concentration, especially if there is different affinity of T4 and T4 analog for antibody. Displacement of T4 from TBG (or TBPA) in effect increases the "free" T4 in the assay tube. This increased T4 (relative to that in the calibrators) is measured in the assay as an increased FF4. Conversely, displacement of relatively less T4 from a low-TBG serum sample is measured in the assay as a low FF4.
We observed a very low dialyzed fraction of T4 and T4 analog from albumin in the absence of blocker, consistent with binding of both by albumin. Increasing blocker concentrations competitively displaced both T4 and T4 analog from albumin, as evidenced by increasing dialyzed fractions. There appeared to be greater displacement of analog than T4 by buffers 4-6, but this may in fact be due to the lower labeled-T4 specific activity (being diluted by endogenous 14). Although a feature of other assays (3, 16), there was no evidence that the DPC T4 analog is bound by TBG. Lower dialyzed fractions in buffers 1-3 are explained by the 1.0 g/L concentration of albumin present in all the buffers, as is demonstrated by the buffer blanks. T4 TBG binding is intact in buffers 1-4, but there is a significant increase in dialyzed 14 in buffers 5 and 6, indicative of T4 displacement from TBG by the blockers present in these two buffers.
We demonstrated that little analog is dialyzable from albumin and that there is little antibody binding of analog added to serum in the absence of blockers (buffer 1), consistent with analog-albumin binding. There was progressive labeled-analog binding to antibody in the presence of serum as blocker concentrations progressively increased in buffers 2-4. The significant fall in labeled-analog binding to antibody in the presence of serum in buffers 5 and 6 is due to T4 release from TBG, with resulting competitive displacement of labeled analog from antibody. We did not demonstrate a
